Ginkgo biloba extract enhances glucose tolerance in hyperinsulinism-induced hepatic cells.
Ginkgo biloba, an herbal medication, is capable of lowering glucose, fat, and lipid peroxide in diabetic patients. In the current study, we tested the hypothesis that Ginkgo biloba extract (GBE) prevented hyperinsulinism-induced glucose intolerance in hepatocytes. We investigated the effects of GBE on glucose consumption, glucokinase activity, and mRNA levels of key genes in glucose metabolism and the insulin signaling pathway. To better show its efficacy, we included a control group that was treated with rosiglitazone, a type of thiazolidinedione (TZD). The data indicated that GBE repressed glucose uptake under normal conditions, while it dramatically improved glucose tolerance under insulin-resistant conditions. Furthermore, after analyzing gene expression, we suggest that GBE chiefly exerts its effects by stimulating IRS-2 transcription. It should be noted that, unlike rosiglitazone, GBE did not stimulate excessive glucose uptake as it improved glucose tolerance. It is said that GBE treatment could avoid drug-induced obesity. Our data suggest that GBE has the potential to prevent insulin resistance and is a promising anti-diabetic drug.
Zhou
Lei
L
Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of the Ministry of Education, College of Life Science and Technology, Huazhong Agricultural University, Wuhan 430070, Hubei, People's Republic of China. zhoulei@mail.hzau.edu.cn
Meng
Qingjie
Q
Qian
Tao
T
Yang
Zaiqing
Z
D002460:Cell Line; D020441:Ginkgo biloba / Q000737:chemistry*; D005941:Glucokinase / Q000235:genetics; D005947:Glucose / Q000378:metabolism*; D005952:Glucose-6-Phosphatase / Q000235:genetics; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D006946:Hyperinsulinism / Q000378:metabolism*; D007328:Insulin / Q000494:pharmacology; D055504:Insulin Receptor Substrate Proteins / Q000235:genetics; D047495:PPAR gamma / Q000235:genetics; D010936:Plant Extracts / Q000737:chemistry* / Q000494:pharmacology*; D012333:RNA, Messenger; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology
C526297:IRS2 protein, human; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; D047495:PPAR gamma; D010936:Plant Extracts; D012333:RNA, Messenger; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D005941:Glucokinase; D005952:Glucose-6-Phosphatase; D005947:Glucose
Endocrinology. 2000 Nov;141(11):4021-31
11089532
Gen Pharmacol. 1999 Nov;33(5):369-75
10553877
Biochem J. 2000 May 15;348 Pt 1:83-91
10794717
Anal Biochem. 1976 May 7;72:248-54
942051
J Clin Pharmacol. 2000 Jun;40(6):647-54
10868316
Pharmacol Res. 2004 Feb;49(2):133-42
14643693
Biol Res. 2000;33(2):159-65
15693283
N Engl J Med. 2004 Sep 9;351(11):1106-18
15356308
Endocrinology. 2001 Apr;142(4):1448-52
11250924
J Clin Invest. 2002 May;109(9):1125-31
11994399
J Clin Invest. 1985 Jul;76(1):22-30
3894420
Diabetes. 2000 Nov;49(11):1880-9
11078455
Nat Cell Biol. 2004 Apr;6(4):351-7
15048126
Diabetes Care. 1990 Mar;13(3):198-208
2407475
J Clin Invest. 2005 Mar;115(3):718-27
15711641
Klin Oczna. 2004;106(4-5):569-71
15646470
Diabetes. 2003 Aug;52(8):1943-50
12882909
J Nat Prod. 1998 Nov;61(11):1386-7
9834158
Diabetes Care. 1999 Jun;22(6):908-12
10372240
Biochem Pharmacol. 2010 Jun 1;79(11):1674-83
20144590
Planta Med. 2002 Jan;68(1):76-9
11842336
J Biol Chem. 1998 Jul 10;273(28):17491-7
9651339
Biochem Pharmacol. 1995 May 26;49(11):1649-55
7786306
J Biol Chem. 1995 Oct 20;270(42):24670-3
7559579